To determine the incidence and severity of cyclosporineinduced graft-versus-host disease following non-myeloablative chemotherapy without progenitor cell reinfusion in patients with acute leukemia, 17 adults with refractory acute myeloid leukemia (14) or blastic phase of chronic myeloid leukemia (3) were treated with etoposide 2400 mg/m 2 and cyclophosphamide 120 mg/kg followed by cyclosporine (CsA) 2.5 mg/kg i.v. daily and interferon gamma 0.025 mg/m 2 subcutaneously every other day until day 28. Skin biopsies were obtained on days 14 and 28, or on the appearance of a skin rash, and graded for GVHD. Blood samples were examined at baseline and weekly starting on day 14 for natural killer (NK) cell and T cell lymphocytic changes. Posttreatment lymphocytes from select patients were assessed for allogeneic NK cell and autologous leukemic cell cytolytic activity. Four patients developed pathologic grade 2 cutaneous acute GVHD. Of the three patients who achieved a complete remission, two had evidence of GVHD. Post-treatment, three patients (two with GVHD) in whom adequate numbers of lymphocytes could be obtained showed NK cell cytolytic activity against allogeneic tumor cells (K562), but none had cytolytic activity against their own cryopreserved leukemic cells. These data suggest that in patients with AML treated with subablative doses of chemotherapy without autotransplant, autologous GVHD can be induced, although at an incidence lower than that reported for CsA-induced GVHD following marrow transplantation. An enhancement of T cell and NK cell activity levels similar to experiences in syngeneic models of autologous GVHD was seen, but no direct autologous leukemic cell cytotoxicity could be demonstrated.
develop graft-versus-host disease (GVHD). [1] [2] [3] Efforts to induce this syndrome following autologous transplantation have involved the use of marrow ablative cytotoxic therapy, reinfusion of autologous progenitor cells, followed by the administration of cyclosporine (CsA) with or without interferon gamma. Using this approach, studies in patients with acute leukemia, breast cancer, and non-Hodgkin's lymphoma have demonstrated that a significant percentage of patients will achieve a clinical syndrome consistent with GVHD. [4] [5] [6] [7] Laboratory studies in mice have also suggested that CsAinduced autologous GVHD can be established with myelosuppressive but not ablative therapy and without progenitor cell reinfusion. 8 Clinically, this approach would eliminate the potential reintroduction of leukemic cells during autologous transplantation, and might avoid some of the non-hematologic toxicity resulting from myeloablative chemo-radiotherapy. Based upon these observations a study was conducted to evaluate whether CsA-induced GVHD could be established in patients with acute leukemia using nonmyeloablative therapy and without progenitor cell reinfusion.
Materials and methods
Adult patients over the age of 15 years with relapsed or refractory acute leukemia or blastic phase of chronic myeloid leukemia were eligible for entry into the trial. Patients were required to have a serum bilirubin and creatinine less than 2 mg/dl and an ECOG performance status of 0-2. Written informed consent was obtained prior to the initiation of treatment.
All patients were treated with an induction regimen consisting of etoposide at a dose of 2400 mg/m 2 administered by continuous infusion over 48-72 h followed by cyclophosphamide at a dose of 60 mg/kg given over 4 h daily ϫ 2 . Twenty-four hours after the completion of cyclophosphamide, cyclosporine, 2.5 mg/kg/day by intravenous infusion over 4 h in two divided doses, and interferon gamma, 0.025 mg/m 2 every other day by subcutaneous injection, were administered until day 28 of the regimen.
Bone marrow aspirates and/or biopsies were obtained 7-10 days after treatment to assess the effectiveness of therapy in clearing the marrow of disease, and weekly therafter to assess remission status. Complete remission (CR) was defined as the achievement of a cellular marrow with Ͻ5% myeloblasts, a granulocyte count of Ͼ1 ϫ 10 9 /l, and a platelet count of 100 ϫ 10 9 /l for a duration of 1 month or longer.
Patients were examined daily for evidence of GVHD. Four-millimeter punch biopsies of the skin were performed on all patients on days 14 and 28 of the treatment regimen to assess pathologic evidence of GVHD. Additional biopsies were done at sites of suspected clinical skin GVHD as indicated.
Clinical grading of GVHD was assessed according to previously published methods. 9 The histologic diagnosis of acute cutaneous GVHD required the demonstration of at least grade 2 acute GVHD changes which included basal vacuolization, altered polarity of epidermal cells, dyskeratosis, and lymphocytic infiltration into the peripheral dermis and epidermis. 10 
Laboratory methods
Peripheral blood samples were assessed pretreatment, on day 14 and weekly thereafter for flow cytometric evaluation of lymphocyte subsets and natural killer (NK) cell levels. Lymphocyte subclasses were quantitated using monoclonal antibodies and immunofluorescent antibody technique. Total T cells (CD3), helper T cells (CD4), cytolytic T cells (CD8), and NK cells (CD16 ϩ CD56) were enumerated using respective antibodies (Becton Dickinson, San Jose, CA, USA) with two-color immunofluorescence determined by Coulter Profile II cytometer (Coulter, Miami, FL, USA).
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Absolute numbers of the total cell populations were derived by multiplication of the percentage of each population to the absolute lymphocyte count obtained by standard WBC count and cell differential.
In selected patients, mononuclear cells were isolated from the peripheral blood weekly starting on day 21 and evaluated for cytotoxic effects against the K562 cell line, as well as for autocytolytic effects against patient leukemic cells collected and stored prior to therapy. Mononuclear cells from the peripheral blood were isolated by FicollHypaque gradient density centrifugation. Mononuclear cells obtained at different time periods after the initial treatment were used as effector cells in the cytotoxicity assay. 12, 13 The viability of such specimens were all greater than 92% after thawing. Target cells were either 51 Cr labeled K562 cells or 51 Cr labeled autologous leukemic cells which were cryopreserved prior to treatment. Cells were labeled with 51 Cr on a rocker platform for 60-90 min. Leukemic target cells were propagated in cultures with RPMI-1640 and 15% FCS for 24 h and specimens with greater than 90% viability were used for labeling. Several effector:target cell ratios were used including 60:1, 15:1 and 4:1. Duplicate experiments were performed for each condition and their means were reported. Percent lysis was calculated as (experiment c.p.m. Ϫ spontaneous c.p.m./maximum c.p.m. Ϫ spontaneous c.p.m.) ϫ 100%.
Results

Patient characteristics
From April 1995 to September 1996, 17 patients, 14 with refractory acute myeloid leukemia (AML) and three in blastic phase of CML, were enrolled in the study (Table 1 ). The median age of patients entered were 59 years (range 32-67). The majority had unfavorable cytogenetics (Ϫ5, Ϫ7, ϩ8 or other miscellaneous abnormalities) and nine had received two or more prior induction regimens.
Treatment outcome
The median duration of CsA administration was 24 days (range 6-24). Three patients were taken off CsA prior to day 14 due to an increase in serum creatinine to greater than 2 ϫ baseline values. One patient developed septicemia and died on day 14 of therapy. One patient who demonstrated rapidly progessive leukemia prior to day 28 was taken off study on day 17 and given alternative therapy. Apart from the development of renal insufficiency, mild hypertension, easily controllable with antihypertensive medication (two patients) was the only toxicity attributable to CsA. No specific toxicity was seen with administration of IFN-gamma. As expected, severe myelosuppression occurred in all patients, and all 17 developed fever with neutropenia requiring intravenous antibiotics. Significant (grade 3-4) non-hematologic toxicity included nausea and vomiting, mucositis and diarrhea, each occurring in three or less patients.
Five patients developed a diffuse erythematous skin rash covering less than 25% of the body surface area. Of these patients, three had biopsies that were consistent with histologic grade 2 GVHD. The other two biopsies showed nonspecific inflammatory changes. One additional patient did not develop a skin rash, but was found to have histologic GVHD on a surveillance skin biopsy. The interval between day 1 of therapy and the development of a positive skin biopsy in the four patients was 15, 28, 28, and 38 days, respectively. These skin manifestations were transient and did not require specific therapy. No other signs of clinical GVHD (ie liver or gut) were observed.
Of the 17 patients entered, three achieved a complete remission with a duration of 2 to 6 months. One patient died on day 14 of therapy due to sepsis and 13 had persistent leukemia documented on marrow examination. Of the three responding patients, two had histologic evidence of GVHD on skin biopsy. The median survival of patients on study was 65 days (range 14-364).
Laboratory results
Although modest in many instances, compared to pretreatment values, the proportion and absolute number of T cells and NK cells increased during therapy in nine of 10 and seven of 10 patients, respectively, in whom serial samples were available. From baseline, the median fold increase in absolute T cells was 4.0 (range 1.2 to 82.5). The timing of NK cell increase coincided generally with the T cell increase. In four patients, including two of the four patients with GVHD, an initial rise in CD4 cells was detected followed by a subsequent predominance in the CD8 population, which occurred 35-60 days from the onset of treatment.
NK cell activity was quantified during the treatment period in three patients. Mononuclear cells prepared from these Table 2 shows that approximately three-to four-fold increases in NK cytolytic activity were detected during the treatment period. Peripheral blood mononuclear cell preparations containing leukemic blasts obtained prior to treatment were also used as target cells in the cytolytic assays. Cytolytic activity against autologous leukemic cells was only detected near baseline levels indicating that mononuclear cells obtained after treatment did not lyse their autologous leukemic cells in any of the samples analyzed.
Discussion
Based on experimental animal models of syngeneic and autologous CsA-induced GVHD, several clinical studies have evaluated the induction of GVHD in patients undergoing autologous marrow transplantation followed by CsA. For example, Yeager et al 4 reported that grade 1-2 skin GVHD developed in 79% of patients with AML undergoing autologous transplantation followed by CsA. A similar frequency of CsA-induced GVHD were reported in patients with non-Hodgkin's lymphoma and breast cancer undergoing autologous transplantation. [5] [6] [7] The current study was conducted primarily to determine the extent and degree of autologous, CsA-induced GVHD following non-myeloablative chemotherapy without progenitor cell reinfusion. The results demonstrated that this effect can occur with nonmyeloablative therapy, but at a frequency significantly less than that following ablative cytotoxic therapy and hematopoietic progenitor cell reinfusion.
The lower incidence of GVHD seen in our study may be related to differences in conditioning regimens as well as length of CsA administration. Animal studies have reported that non-irradiated animals treated with CsA alone rarely develop GVHD, unless CsA is administered over a prolonged time period (Ͼ6 months). [14] [15] [16] These and other studies have suggested that the principle effect of the cytotoxic agents in the auto-GVHD process is the elimination of peripheral T-lymphocyte dependent regulatory mechanisms which enhance the ability of CsA to induce the auto-GVHD syndrome and that the degree of ablation of peripheral T cell regulation may be dose-dependent and specific to the cytotoxic agent used. 17, 18 For example, in rodent studies, suppression of T cell regulation with total body irradiation and cyclophosphamide, was sufficient to induce GVHD following 4 weeks of CsA. 19 In contrast, rats treated with busulfan alone only developed autologous GVHD after prolonged (10-12 weeks) exposure to CsA. 20 In the study by Yeager et al, 4 cyclophosphamide was administered at a dose of 200 mg/kg compared to the 120 mg/kg given to patients in our study. Etoposide is an effective myelosuppressive drug but its ability to contribute to the suppression of T cell autoregulation has not been previously demonstrated. Since patients on our study received on average 24 days of CsA it may be that the combination of a relatively weak immunosuppressive conditioning regimen, coupled with a short duration of CsA administration, explains the significantly lower induction of GVHD.
It is not clear whether the reinfusion of autologous hematopoietic cells enhances the development of GVHD. In the transplant studies involving patients with breast cancer and AML, the onset of CsA-induced GVHD appeared in many instances unrelated to the detection of circulating lymphocytes. On the other hand, the reinfusion of stored lymphocytes along with the other hematopoietic progenitor cells, may have allowed for a relatively early presence of immunocompetent circulating lymphocytes, coinciding with the administration of CsA. In our study, CsA was discontinued at day 28 which may have been prior to significant immune reconstitution.
The decreased incidence of autologous GVHD observed in this study compared to experiences in patients undergoing marrow transplantation may also have resulted from the lack of CRs achieved in this study compared to the patients reported in the transplant studies. In the study by Yeager et al, 4 all 19 patients with AML who underwent autologous marrow transplantation followed by CsA were in a complete remission at the time of transplant, including 12 transplanted in first remission. Since very few patients in the present trial cleared their bone marrow of leukemia, this may have translated into fewer lymphocytes in the effector population following chemotherapy to generate the target immune responses.
Evidence of an effect on T cell lymphocyte and NK cell populations was observed in the majority of patients evaluated. In particular, the predominance of CD8 cells seen in four of the patients, including two of the four patients with GVHD, although incrementally modest, is similar in pattern to that observed in other studies with CsA-induced autologous GVHD. Experiments in rodents have shown both in vitro and in vivo antitumor effects associated with CsAinduced GVHD using an Ia-bearing rat plasmacytoma cell line. 21 Clinical studies of autologous transplantion followed by CsA in lymphoma have demonstrated the presence of post-transplant lymphocytes that had cytolytic activity against autologous pretransplant lymphocytes. 5 The increase of NK and T cell activity in patients treated on this study demonstrated the ability to lyse radiolabeled K562 cells. Treatment of patients with active AML allowed us the opportunity to assess whether a direct anti-leukemic cytotoxic T cell effect would be generated against autologous leukemic blast cells obtained pretreatment. The results of these studies were somewhat disappointing in that the NK and T cell cytolytic activity against their own leukemic cells could not be demonstrated. Possible underlying reasons for this include the absence of specific killer cells for autologous tumor cells, a suboptimal ratio of tumor and effector cells, or the relatively quiescent nature of the leukemic cells, resulting in ineffective radiolabelling. Alternatively, it is possible that CsA-treated lymphocytes may lack a proper signal through the T cell receptor to initiate an effector mechanism.
The overall lack of significant clinical response, and relatively low incidence of GVHD seen in this study clearly discourage the use of this approach in patients with refractory leukemia. It is difficult to detect an antileukemic immune response in patients with refractory acute leukemia and blastic phase of CML. The demonstration of autologous GVHD with non-ablative therapy in some patients, however, suggests that with further development, this may be an effective antileukemic strategy if employed in a more favorable setting ie during the postremission phase of treatment. In this setting, immunosuppressive, sub-myeloablative chemotherapy followed by CsA might allow an immunomodulatory antileukemic effect without requiring ablative, more toxic doses of cytotoxic therapy and the potential for reinfusion of leukemic cells.
